Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Chun, Loo Gan"'
Autor:
Nicholas A. Bosma, Matthew T. Warkentin, Chun Loo Gan, Safiya Karim, Daniel Y.C. Heng, Darren R. Brenner, Richard M. Lee-Ying
Publikováno v:
European Urology Open Science, Vol 37, Iss , Pp 14-26 (2022)
Context: Considerable advances have been made in the first-line treatment of metastatic renal cell carcinoma (mRCC), with immunotherapy-based combinations including immunotherapy-tyrosine kinase inhibitors (IO-TKIs) and dual immunotherapy (IO-IO) fav
Externí odkaz:
https://doaj.org/article/c580ba678b22489b80abd48ba7373998
Autor:
Chun Loo Gan, Shaan Dudani, J. Connor Wells, Frede Donskov, Sumanta K. Pal, Nazli Dizman, Nityam Rathi, Benoit Beuselinck, Flora Yan, Aly‐Khan A. Lalani, Aaron Hansen, Bernadett Szabados, Guillermo deVelasco, Ben Tran, Jae Lyun Lee, Ulka N. Vaishampayan, Georg A. Bjarnason, Mathushan Subasri, Toni K. Choueiri, Daniel Y. C. Heng
Publikováno v:
Cancer Medicine, Vol 10, Iss 4, Pp 1212-1221 (2021)
Abstract Background Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns of cabozantinib are not well characterized. Methods Patients with
Externí odkaz:
https://doaj.org/article/7d15b141c0ef4643936c243f3bc0a02a
Autor:
Chun, Loo Gan, Jiaming, Huang, Elizabeth, Pan, Wanling, Xie, Andrew L, Schmidt, Chris, Labaki, Luis, Meza, Gabrielle, Bouchard, Haoran, Li, Francesca, Jackson-Spence, Carla, Sánchez-Ruiz, Thomas, Powles, Shruti A, Kumar, Nicole, Weise, William A, Hall, Brent S, Rose, Benoit, Beuselinck, Cristina, Suarez, Sumanta K, Pal, Toni K, Choueiri, Daniel Y C, Heng, Rana R, McKay
Publikováno v:
European Urology Oncology. 6:204-211
There is a paucity of data on the safety of cabozantinib use in combination with radiotherapy.To report the practice patterns, safety, and efficacy of cabozantinib with radiotherapy in metastatic renal cell carcinoma (mRCC).An international multicent
Autor:
Ziad Bakouny, Talal El Zarif, Shaan Dudani, J. Connor Wells, Chun Loo Gan, Frede Donskov, Julia Shapiro, Ian D. Davis, Francis Parnis, Praful Ravi, John A. Steinharter, Neeraj Agarwal, Ajjai Alva, Lori Wood, Anil Kapoor, Jose M. Ruiz Morales, Christian Kollmannsberger, Benoit Beuselinck, Wanling Xie, Daniel Y.C. Heng, Toni K. Choueiri
Publikováno v:
European Urology. 83:145-151
The role of upfront cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) in the era of immune checkpoint inhibitors is unclear.To evaluate the relationship between upfront CN and clinical outcomes in the setting of mRCC treated w
Autor:
Christian Kollmannsberger, Ben Tran, Aaron R. Hansen, Guillermo Velasco, Daniel Y.C. Heng, Daniel Vilarim Araujo, M. Neil Reaume, Takeshi Yuasa, Connor Wells, Georg A. Bjarnason, Benoit Beuselinck, Chun Loo Gan, D. Scott Ernst, Flora Yan, Shaan Dudani, Frede Donskov, Sumanta K. Pal, Thomas Powles, Nazli Dizman, Toni K. Choueiri
Publikováno v:
Araujo, D V, Wells, J C, Hansen, A R, Dizman, N, Pal, S K, Beuselinck, B, Donskov, F, Gan, C L, Yan, F, Tran, B, Kollmannsberger, C K, de Velasco, G, Yuasa, T, Reaume, M N, Ernst, D S, Powles, T, Bjarnason, G A, Choueiri, T K, Heng, D Y C & Dudani, S 2021, ' Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis ', Journal of Geriatric Oncology, vol. 12, no. 5, pp. 820-826 . https://doi.org/10.1016/j.jgo.2021.02.022
5068 Background: Anti-PD-1/PD-L1 immune-checkpoint inhibitors (ICI) are now a standard of care in metastatic renal cell carcinoma (mRCC). Older adults were underrepresented in registration trials and given that immunological senescence may affect the
Autor:
Nazli Dizman, Bernadett Szabados, Sumanta K. Pal, Frede Donskov, Toni K. Choueiri, Guillermo Velasco, Benoit Beuselinck, Chun Loo Gan, Daniel Y.C. Heng, Aly-Khan A. Lalani, Ulka N. Vaishampayan, J. Connor Wells, Aaron R. Hansen, Nityam Rathi, Georg A. Bjarnason, Ben Tran, Flora Yan, Shaan Dudani, Jae-Lyun Lee, Mathushan Subasri
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 4, Pp 1212-1221 (2021)
Gan, C L, Dudani, S, Wells, J C, Donskov, F, Pal, S K, Dizman, N, Rathi, N, Beuselinck, B, Yan, F, Lalani, A K A, Hansen, A, Szabados, B, de Velasco, G, Tran, B, Lee, J L, Vaishampayan, U N, Bjarnason, G A, Subasri, M, Choueiri, T K & Heng, D Y C 2021, ' Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma : Results from the International Metastatic Renal Cell Carcinoma Database Consortium ', Cancer Medicine, vol. 10, no. 4, pp. 1212-1221 . https://doi.org/10.1002/cam4.3717
Cancer Medicine, Vol 10, Iss 4, Pp 1212-1221 (2021)
Gan, C L, Dudani, S, Wells, J C, Donskov, F, Pal, S K, Dizman, N, Rathi, N, Beuselinck, B, Yan, F, Lalani, A K A, Hansen, A, Szabados, B, de Velasco, G, Tran, B, Lee, J L, Vaishampayan, U N, Bjarnason, G A, Subasri, M, Choueiri, T K & Heng, D Y C 2021, ' Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma : Results from the International Metastatic Renal Cell Carcinoma Database Consortium ', Cancer Medicine, vol. 10, no. 4, pp. 1212-1221 . https://doi.org/10.1002/cam4.3717
Background Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns of cabozantinib are not well characterized. Methods Patients with mRCC trea
Autor:
Chun Loo Gan, John Kourambas, Nicholas Redgrave, Sree Appu, Andrew Coleman, Geoffrey Soo, Edmond M. Kwan, Shakher Ramdave, Jason Bradley, Amy Davies, Eva Segelov, Scott Williams, Marcus Foo, Arun Azad, Scott Donnellan
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 18
Objective PSMA PET/CT has demonstrated superior sensitivity over conventional imaging in the detection of local and distant recurrence in biochemically relapsed (BCR) prostate cancer. We prospectively investigated the management impact of 68 Ga-PSMA
Autor:
Shivanshan Pathmanathan, Arsalan Tariq, Chun Loo Gan, Adam Pearce, Handoo Rhee, Samuel Kyle, Sheliyan Raveenthiran, David Wong, Rhiannon McBean, Philip Marsh, Steven Goodman, Nattakorn Dhiantravan, Rachel Esler, Nigel Dunglison, Anojan Navaratnam, John Yaxley, Paul Thomas, David A. Pattison, Jeffrey C. Goh, Matthew Roberts
Publikováno v:
Journal of Clinical Oncology. 40:4540-4540
4540 Background: There is emerging role of the use of PSMA PET in RCC. Herein, we report our experience in use of PSMA PET in recurrent or metastatic RCC in Brisbane, Australia. Methods: Patients (pts) who underwent PSMA PET and conventional diagnost
Autor:
Sabina Signoretti, Laure Hirsch, Adam S. Feldman, Thomas Denize, Xin Gao, Jiao Li, Jihye Park, Gwo-Shu Mary Lee, Emma R. Garner, Chris Labaki, Daniel Y.C. Heng, Ananthan Sadagopan, Ziad Bakouny, Catherine J. Wu, David F. McDermott, Bradley Alexander McGregor, Vidyalakshmi Sethunath, Eliezer M. Van Allen, Filipe Lf Carvalho, Natalie I. Vokes, Steven L. Chang, Shaan Dudani, Shatha AbuHammad, Toni K. Choueiri, Stephen Tang, Chun-Loo Gan, Praful Ravi, Nebiyou Y. Metaferia, Michelle S. Hirsch, Emily Walton, David A. Braun, Rizwan Haq, Destiny West, Srinivas R. Viswanathan, Gabrielle Bouchard, Alma Imamovic, Cora A. Ricker, John A. Steinharter, Jackson Nyman
Translocation renal cell carcinoma (tRCC) is an aggressive and poorly-characterized subtype of kidney cancer driven by MiT/TFE gene fusions. Here, we define the landmarks of tRCC through an integrative analysis of 152 tRCC patients identified across
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6950b889cd81d344eda797d5061d34d3
https://doi.org/10.1101/2021.04.14.439908
https://doi.org/10.1101/2021.04.14.439908
Publikováno v:
Can Urol Assoc J